These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

358 related items for PubMed ID: 12828606

  • 1. Microinvasive ductal carcinoma (T1mic) of the breast. The clinicopathological profile and immunohistochemical features of 28 cases.
    Yang M, Moriya T, Oguma M, De La Cruz C, Endoh M, Ishida T, Hirakawa H, Orita Y, Ohuchi N, Sasano H.
    Pathol Int; 2003 Jul; 53(7):422-8. PubMed ID: 12828606
    [Abstract] [Full Text] [Related]

  • 2. Immunohistochemical analysis on biological markers in ductal carcinoma in situ of the breast.
    Iwase H, Ando Y, Ichihara S, Toyoshima S, Nakamura T, Karamatsu S, Ito Y, Yamashita H, Toyama T, Omoto Y, Fujii Y, Mitsuyama S, Kobayashi S.
    Breast Cancer; 2001 Jul; 8(2):98-104. PubMed ID: 11342981
    [Abstract] [Full Text] [Related]

  • 3. Correlation of the ultrasound imaging of breast cancer and the expression of molecular biological indexes.
    Xu J, Li F, Chang F.
    Pak J Pharm Sci; 2017 Jul; 30(4(Suppl.)):1425-1430. PubMed ID: 29043992
    [Abstract] [Full Text] [Related]

  • 4. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.
    Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J, Sanchez H, Jimenez C, Stewart K, Chew K, Ljung BM, Tlsty TD.
    J Natl Cancer Inst; 2010 May 05; 102(9):627-37. PubMed ID: 20427430
    [Abstract] [Full Text] [Related]

  • 5. Clinicopathological Follow-up of Breast DCIS Diagnosed on Biopsies: A Single Institutional Study of 575 Patients.
    Yan M, Bomeisl P, Gilmore H, Harbhajanka A.
    Int J Surg Pathol; 2021 Dec 05; 29(8):836-843. PubMed ID: 33890815
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Oestrogen receptor negativity as a marker for high-grade ductal carcinoma in situ of the breast.
    Baqai T, Shousha S.
    Histopathology; 2003 May 05; 42(5):440-7. PubMed ID: 12713620
    [Abstract] [Full Text] [Related]

  • 12. Expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67 in ductal carcinoma in situ (DCIS) and DCIS with microinvasion.
    Wan ZB, Gao HY, Wei L, Zhang AQ, Zhang JY, Wang Y, Wang DD, Zhang Y.
    Medicine (Baltimore); 2018 Nov 05; 97(44):e13055. PubMed ID: 30383678
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Factors predicting microinvasion in Ductal Carcinoma in situ.
    Ozkan-Gurdal S, Cabioglu N, Ozcinar B, Muslumanoglu M, Ozmen V, Kecer M, Yavuz E, Igci A.
    Asian Pac J Cancer Prev; 2014 Nov 05; 15(1):55-60. PubMed ID: 24528005
    [Abstract] [Full Text] [Related]

  • 18. Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile.
    Dabbs DJ, Chivukula M, Carter G, Bhargava R.
    Mod Pathol; 2006 Nov 05; 19(11):1506-11. PubMed ID: 16941011
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.